HIV fusion and its inhibition in antiretroviral therapy

Reviews in Medical Virology
Michael L GreenbergLynn Smiley

Abstract

The end of the twentieth century saw dramatic improvements in the prognosis of HIV infection brought about by the introduction of new agents (the protease inhibitors and the non-nucleoside reverse transcriptase inhibitors) and their use in highly active combinations. However, the durability of these combination treatments is limited by a number of factors including adverse effects and extensive intra-class cross-resistance so that new antiretrovirals acting on alternative targets and having improved systemic tolerability profiles are required. The HIV binding and entry process offers several potential targets for antiviral interaction. These include gp120 binding to CD4 and to chemokine co-receptor molecules as well as the fusion process itself, which involves interactions between two leucine zipper-like 4-3 repeat regions within gp41 known as heptad repeat (HR)1 and HR2. Peptides such as enfuvirtide (formerly DP178 or T-20), that mimic the HR2 region of gp41, inhibit HIV-1 by a mechanism that is thought to involve competitive binding to HR1. This review summarises the clinical development of enfuvirtide, providing an overview of the pharmacokinetic, efficacy and safety data in various patient populations, and also considers th...Continue Reading

Citations

May 12, 2012·The Journal of Biological Chemistry·Amber A BentleyAnton A Komar
Nov 28, 2012·The Journal of Biological Chemistry·Guofen GaoVenigalla B Rao
Jan 11, 2008·AIDS Research and Human Retroviruses·T MelbyM L Greenberg
Oct 16, 2007·Clinical Microbiology Reviews·Carrie Dykes, Lisa M Demeter
May 13, 2008·Drug Discovery Today·Catherine S Adamson, Eric O Freed
Apr 21, 2005·Cellular Microbiology·Candace Gomez, Thomas J Hope
Mar 25, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Matthias EngelkeStephan Urban
Sep 17, 2013·Journal of Medical Virology·Mônica Nogueira da Guarda ReisMariane Martins Araújo Stefani
Oct 15, 2009·Reviews in Medical Virology·M I Qadir, S A Malik
Feb 22, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·R CarmonaR Nájera
May 9, 2006·Trends in Microbiology·Charles J Russell, Laura E Luque
Oct 4, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Saleta SierraRolf Kaiser
Mar 30, 2005·Expert Opinion on Pharmacotherapy·Adriano Lazzarin
Apr 25, 2006·Virology·Mark J BisconeJacqueline D Reeves
Aug 16, 2005·Expert Review of Proteomics·Oliver K BernhardAnthony L Cunningham
Aug 26, 2006·Journal of Leukocyte Biology·Stefano AquaroCarlo Federico Perno
Aug 22, 2007·Reviews in Medical Virology·P D GriffithsY Shao
Mar 18, 2005·The Journal of Biological Chemistry·Tara R Suntoke, David C Chan
Aug 7, 2007·Journal of Biomolecular Structure & Dynamics·Wu YingliangLi Wenxin
May 12, 2010·Acta Biochimica Et Biophysica Sinica·Zhiqiang WangCheng-Wu Chi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Antiviral Chemistry & Chemotherapy
Fusako Miyamoto, Eiichi N Kodama
Proceedings of the National Academy of Sciences of the United States of America
Jacqueline D ReevesRobert W Doms
Proceedings of the National Academy of Sciences of the United States of America
D M LambertS R Petteway
Proceedings of the National Academy of Sciences of the United States of America
J P Moore, Robert W Doms
© 2021 Meta ULC. All rights reserved